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OBJECTIVE—Glucagon-like peptide (GLP)-1 lowers postpran-
dial glycemia primarily through inhibition of gastric emptying. We
addressed whether the GLP-1–induced deceleration of gastric
emptying is subject to rapid tachyphylaxis and if so, how this
would alter postprandial glucose control.
RESEARCH DESIGN AND METHODS—Nine healthy volun-
teers (25 6 4 years old, BMI: 24.6 6 4.7 kg/m
2) were examined
with intravenous infusion of GLP-1 (0.8 pmol $ kg
21.min
21)o r
placebo over 8.5 h. Two liquid mixed meals were administered at
a 4-h interval. Gastric emptying was determined, and blood sam-
ples were drawn frequently.
RESULTS—GLP-1 decelerated gastric emptying signiﬁcantly
more after the ﬁrst meal compared with the second meal (P =
0.01). This was associated with reductions in pancreatic polypep-
tide levels (marker of vagal activation) after the ﬁrst but not the
second meal (P , 0.05). With GLP-1, glucose concentrations de-
clined after the ﬁrst meal but increased after the second meal
(P , 0.05). The GLP-1–induced reductions in postprandial insulin
and C-peptide levels were stronger during the ﬁrst meal course
(P , 0.05). Likewise, glucagon levels were lowered by GLP-1 after
the ﬁrst meal but increased after the second test meal (P , 0.05).
CONCLUSIONS—The GLP-1–induced delay in gastric emptying
is subject to rapid tachyphylaxis at the level of vagal nervous
activation. As a consequence, postprandial glucose control by
GLP-1 is attenuated after its chronic administration. Diabetes
60:1561–1565, 2011
T
herapeutic approaches based on the actions
of the incretin hormone glucagon-like peptide
(GLP)-1 have been widely established in the
management of type 2 diabetes (1–3). Although
the glucose-lowering effect of GLP-1 in the fasting state is
primarily mediated by its glucose-dependent augmentation
of insulin secretion and inhibition of glucagon release
(4,5), the key mechanism driving the postprandial nor-
malization of glycemia by GLP-1 is a marked deceleration
of gastric emptying leading to a delayed entry of glucose
into the circulation (6–9). In fact, when the deceleration of
gastric emptying by GLP-1 is antagonized, the glucose-
lowering effect of the incretin is largely abolished (10).
Although a longer duration of action covering the entire
24 h of the day is generally thought to confer improved
glycemic control, constant activation of the GLP-1 re-
ceptor might also lead to the induction of tolerance against
the incretin hormone, thereby possibly reducing its po-
tency. In analogy, the development of tachyphylaxis is well
known to alter the actions of nitrates or catecholamines
during constant pharmacologic exposure (11,12). Whether
the actions of GLP-1 are also subject to tachyphylaxis has
not yet been examined. However, when GLP-1 was admin-
istered intravenously over a period of 7 days in patients
with type 2 diabetes, postprandial glucose concentrations
declined after serving the ﬁrst meal, whereas an increment
in postprandial glucose levels was observed after the sub-
sequent meal courses (13). Unfortunately, gastric emptying
measurements were not available from that study or any
other study with chronic GLP-1 administration over re-
peated meal courses.
Therefore, the current study addressed whether the
deceleration of gastric emptying by intravenous GLP-1 is
subject to rapid tachyphylaxis and if so, whether this can
lead to clinically relevant differences in postprandial gly-
cemic control.
RESEARCH DESIGN AND METHODS
Study protocol. The study protocol was approved by the ethics committee of
the medical faculty of Ruhr University, Bochum, Germany (registration number
652 a) before study commencement. Written informed consent was obtained
from all participants.
Subjects. Nine healthy male volunteers were studied. They were 25 6 4 years
old with a BMI of 24.6 6 4.7 kg/m
2. All had a normal oral glucose tolerance
according to World Health Organization criteria (fasting glucose 5.1 6 0.4,
120-min value 5.0 6 1.1 mmol/L). None had a family history of diabetes or a
personal history of gastrointestinal disorders. Blood cell counts, serum trans-
aminases, creatinine values, triglyceride, cholesterol, and HDL-cholesterol con-
centrations were in the normal range.
Study design. All participants were studied, in random order, on two occa-
sions:
1) Liquid mixed meals (50 g sucrose plus amino acids, 400 mL Aminosteril
N-Hepa 8%; Fresenius AG, Bad Homburg, Germany) were instilled intra-
gastrically at time 0 and 240 min. Placebo (0.9% NaCl with 1% human serum
albumin, Human-Albumin 20% Behring, salzarm, Behringwerke AG, Marburg,
Germany) was infused intravenously from 230 to 480 min.
2) Liquid test meals were administered as described. In addition, a con-
tinuous intravenous administration of GLP-1 [7–36 amide], at a dose of
0.8 pmol $ kg
21 $ min
21, was started 30 min before the ﬁrst meal (at
230 min) and continued until 480 min.
An interval of 1–4 weeks was kept in between the experiments to avoid
carry-over effects.
Peptides. Synthetic GLP-1 [7–36 amide] was purchased from Saxon Bio-
chemicals GmbH (Hannover, Germany) and processed for infusion as de-
scribed (10).
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ORIGINAL ARTICLEExperimental procedures. The tests were performed in the morning after an
overnight fast. Two forearm veins were punctured with a Teﬂon cannula
(Moskito 123, 18 gauge, Vygon, Aachen, Germany) and kept patent using 0.9%
NaCl (for blood sampling and GLP-1/placebo administration).
After drawing basal blood specimens, at 230 min an intravenous infusion of
GLP-1 [7–36 amide], 0.8 pmol $ kg
21.min
21, or placebo (0.9% NaCl containing
1% human serum albumin) was started and continued for 510 min. This in-
fusion rate was based on previous studies (5,14) and was selected to increase
plasma GLP-1 concentrations into the pharmacologic range (approximately
three- to fourfold higher concentrations in comparison with those measured
after oral glucose) (15). The infusion was begun at 230 min to ensure elevated
GLP-1 [7–36 amide] plasma concentrations already at the time point of ad-
ministration of the ﬁrst liquid meal. Blood was drawn at the time points in-
dicated in Fig. 1, and plasma glucose was determined immediately.
Gastric emptying. Beforethestudy,anasogastrictube(Freka-Ernährungssonde,
120 cm, CH12, Fresenius AG) was placed and tape-ﬁxed with the tip ap-
proximately 55 cm from the nostrils. Gastric juice was aspirated, and an acidic
pH was ascertained using pH-sensitive Lackmus paper. The gastric lumen was
washed with 100 mL water (37°C). The position of the tube was, if necessary,
adjusted to allow a near-complete aspiration of instilled ﬂuid. The subjects
were lying on their back in a semirecumbent position with the upper half of
the body 45 degrees upright. At 0 min, 400 mL (total volume) of the liquid test
FIG. 1. Plasma concentrations of GLP-1 (A), glucose (C), insulin (D), glucagon (E), C-peptide (F), PP (G), and GIP (H), and gastric emptying (B)
after instilling two liquid test meals (amino acids and sucrose) via a nasogastric tube into the stomach at 0 and 240 min in nine healthy young
volunteers during the intravenous infusion of GLP-1 (0.8 pmol $ kg
21 $ min
21) or placebo. Mean 6 SEM. P values were calculated by repeated-
measures ANOVA. *Signiﬁcant (P < 0.05) differences at speciﬁc time points between experiments with placebo and GLP-1. †Signiﬁcant difference
from the corresponding time point after the ﬁrst meal during the exogenous administration of GLP-1.
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50 g sucrose dissolved in 400 mL of mixed amino acids.
This composition of the meal was chosen because the solution had to be
clear for the photometric measurement of phenol red (measurement of gastric
emptying, see below) and should be similar in caloric and nutrient content to
a normal mixed meal. The meal contained 32 g mixed amino acids (131 kCal =
40%) and 50 g sucrose (196 kCal = 60%); total energy content was 327 kCal
(energy density: 0.82 kCal/mL).
Gastric emptying was measured as described (10) using a double-sampling
dye dilution technique using phenol red (Merck AG, Darmstadt, Germany)
according to George (16), with modiﬁcations introduced to reduce measure-
ment error by Hurwitz (17). According to the expected rate of gastric emp-
tying, gastric contents were determined at intervals shown in Fig. 1 over
480 min.
Blood specimens. Blood was drawn into chilled tubes containing EDTA
and aprotinin (Trasylol; 20,000 KIU/mL, 200 mL per 10 mL blood; Bayer AG,
Leverkusen, Germany) and kept on ice. A sample (;100 mL) was stored in
NaF (Microvette CB 300; Sarstedt, Nümbrecht, Germany) for the measurement
of glucose. After centrifugation at 4°C, plasma for hormone analyses was kept
frozen at 230°C.
Laboratory determinations. Glucose was measured using a glucose oxidase
method, as described (10). Insulin was measured using an insulin microparticle
enzyme immunoassay (IMx Insulin, Abbott Laboratories, Wiesbaden, Germany),
as described (10). C-peptide was measured using C-peptide-antibody–coated
microtiter wells (C-peptide MTPL EIA) from DRG Instruments GmbH, Marburg,
Germany, as described (10). Plasma concentrations of total GLP-1 were
determined in ethanol-extracted plasma as previously described (15,18), using
antiserum 89 390 for the measurement of intact GLP-1 [7–36 amide] plus
cleavage products. Pancreatic glucagon was assayed in ethanol-extracted
plasma using antibody 4305 (19). Plasma gastric inhibitory polypeptide (GIP)
was determined by RIA using antiserum R 65 as previously described (20).
Plasma pancreatic polypeptide (PP) was determined by RIA as described (21).
Each patient’s set of plasma samples was assayed at the same time to avoid
errors due to interassay variation.
Phenol red in gastric contents was assayed photometrically after ﬁltration
through ﬁlter paper (100 mL in 2 mL Na2HPO4/NaH2PO4 buffer, 0.6 mol/L/L,
pH 8.0) at a wavelength of 546 nm and read against a standard curve (phenol
red in phosphate buffer).
Statistical analysis. Results are reported as mean 6 SEM. All statistical
calculations were carried out using paired repeated-measures ANOVA using
Statistica version 5.0 (Statsoft Europe, Hamburg, Germany). This analysis
provides P values for the comparison between the two experiments, for
changes over the time course, and for the interaction of experiment and time
course. In case of a signiﬁcant interaction between experiment and time
course, values at individual time points were compared using Student t tests.
To determine differences between the two test meals, the experiment was
divided into two periods, whereby the ﬁrst meal course was evaluated from t =
230 to 240 min, and the second meal course was evaluated from t = 210 to
480 min. Separate paired repeated-measures ANOVA analyses were performed
to compare these periods during placebo and GLP-1 administration, respectively.
A two-sided P value , 0.05 was taken to indicate signiﬁcant differences. Linear
regression analyses were performed to determine the relationship between
gastric emptying and postprandial glycaemia, using GraphPad Prism, Version 4.0.
RESULTS
GLP-1 plasma concentrations. During the placebo ex-
periments, meal ingestion led to an increment in plasma
GLP-1 concentrations from basal levels of 5 6 1 pmol/L to
peak levels of 11 6 2 pmol/L and 11 6 2 pmol/L after the
ﬁrst and second test meals, respectively (P , 0.05; Fig. 1A).
Exogenous GLP-1 administration rapidly increased GLP-1
concentrations to steady-state levels of 50–55 pmol/L (P ,
0.0001 vs. placebo), with superimposed small increments
after the meal administrations. No major adverse outcome
was reported during the experiments.
Gastric empyting. The velocity of gastric emptying was
signiﬁcantly retarded by exogenous GLP-1 compared with
placebo, both after the ﬁrst and second meals (P , 0.0001
for the comparison of GLP-1 vs. placebo over the time
course; Fig. 1B). When gastric emptying was compared
between the two test meals (period 1 vs. 2) during GLP-1
infusion, a signiﬁcant interaction between period and time
course was found (P = 0.010), and subsequent post hoc
tests revealed signiﬁcant differences in gastric volume 120
min after meal administration (Fig. 1B). On the basis of
these analyses, GLP-1 signiﬁcantly slowed gastric empty-
ing after both test meals (periods 1 and 2), but the degree
by which gastric emptying was slowed was less prominent
120 min after meal ingestion with the second meal. When
only the experiments with placebo administration were
analyzed, no signiﬁcant differences in gastric emptying
were found between the experiments (periods) over the
time course (P = 0.38; Fig. 1B).
Postprandial concentrations of glucose, insulin, and
C-peptide. During placebo administration, there was a
small increment in glycemia after the instillation of both
meals (from 4.9 6 0.1 mmol/L at t = 230 min to 6.4 6 0.2
mmol/L at t = 30 min, and from 4.6 6 0.1 mmol/L to 6.1 6
0.3 mmol/L after the second meal, P , 0.05, respectively;
Fig. 1C). Postprandial plasma glucose levels were lower
with concomitant GLP-1 infusions over 60 min after ad-
ministering the meals (P , 0.05; Fig. 1C).
However, although postprandial glucose concentrations
were lowered by GLP-1 during the ﬁrst hour after the ﬁrst
meal (from 5.0 6 0.1 mmol/L at t = 230 min to 4.4 6 0.2
mmol/L at t = 30 min), there was even a small increment in
glycemia after the second meal (from 4.5 6 0.1 mmol/L to
5.2 6 0.2 mmol/L, respectively). The differences in post-
prandial glucose concentrations during GLP-1 infusion be-
tween the ﬁrst meal and the second meal were statistically
signiﬁcant (P , 0.05).
Plasma insulin and C-peptide concentrations increased
signiﬁcantly after instillation of both the ﬁrst and second
test meals during the placebo experiments (P , 0.001,
respectively; Fig. 1D and F). GLP-1 administration led to
an increase in fasting insulin and C-peptide concentrations
(P , 0.05 vs. placebo). However, the postprandial increases
in insulin and C-peptide levels were ;80 and ;55% lower,
respectively, during GLP-1 infusion compared with placebo
(P , 0.001; Fig. 1D and F). The GLP-1–induced reduction in
postprandial insulin and C-peptide concentrations was less
pronounced during the second test meal (P , 0.05 vs. the
ﬁrst meal).
Pancreatic glucagon. Instillation of the test meals resulted
in a clear increase in plasma glucagon concentrations dur-
ing the placebo experiments (Fig. 1E). GLP-1 administration
led to a reduction in both fasting and postprandial glucagon
levels (P = 0.0009). However, with GLP-1, glucagon con-
centrations were higher after the second test meal than
after the ﬁrst test meal (P , 0.05), whereas no differences in
postprandial glucagon levels were observed in the placebo
experiments.
GIP. GIP plasma concentrations increased by approxi-
mately fourfold after the test meals during placebo admin-
istration (Fig. 1H). With exogenous GLP-1, the increments
in GIP plasma levels were blunted and retarded after the
ﬁrst meal, whereas a rapid increment was observed after
the second meal. The peak plasma levels of GIP were sig-
niﬁcantly lower after the ﬁrst test meal compared with the
second test meal during GLP-1 infusion (P , 0.05), whereas
postprandial GIP levels were similar after both meals during
placebo administration (Fig. 1H).
PP. Meal ingestion elicited an increase in PP concen-
trations during placebo administration (Fig. 1G). GLP-1
infusion led to a signiﬁcant reduction in postprandial PP
concentrations after the ﬁrst test meal (P , 0.05; Fig. 1G).
However, PP levels after the second test meal were higher
than after the ﬁrst meal in the GLP-1 experiments, although
there was still a signiﬁcant difference in postprandial PP
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(P , 0.05).
Relationship between gastric emptying and postprandial
glycemia. To determine the impact of gastric emptying on
postprandial glycemia, linear regression analyses between
the parameters of gastric emptying and the respective
glucose increments after the liquid meal were performed.
Across all experiments (with GLP-1 and placebo, analyzing
both the ﬁrst and the second periods), the percentage
of initial gastric volume that had emptied within 60 min
correlated signiﬁcantly with the increment in glucose con-
centrations (peak minus basal concentrations; r
2 =0 . 1 9 4 ,
P = 0.0044). Likewise, 60-min emptying correlated sig-
niﬁcantly with peak glucose concentrations (r
2 =0 . 3 2 7 ,
P , 0.0001) and the time of the glucose peak after the
meal (r
2 =0 . 2 6 5 ,P = 0.0007), but not with the integrated
incremental glucose area (above baseline; r
2 =0 . 0 2 2 ,P =
0.37). Qualitatively similar (highly signiﬁcant) results were
obtained when the gastric emptying half-time, the lag time,
or the 30-min emptying were used instead to characterize
the velocity of gastric emptying (details not shown; an ex-
ample is shown in Supplementary Figure 1).
DISCUSSION
The current study was designed to examine whether the
deceleration of gastric emptying by GLP-1 is subject to
rapid tachyphylaxis and how this would affect post-
prandial glucose homeostasis. We report that the GLP-1–
induced deceleration of gastric emptying is signiﬁcantly
diminished already after 5 h of continuous infusion com-
pared with its initial effects. This attenuation of GLP-1 ef-
ﬁcacy leads to increased postprandial concentrations of
glucose, insulin, and glucagon, as well as changes in the
concentration time pattern of GIP.
A deceleration of gastric emptying by GLP-1 has been
demonstrated in patients with type 2 diabetes and healthy
individuals (5,8,14). In line with these studies, the GLP-1–
induced delay in gastric emptying not only prevented the
postprandial increase in glycemia but also led to a marked
reduction in insulin and C-peptide levels. The GLP-1–
induced reduction in postprandial glycemia and insulin
secretion was less pronounced during the second meal
course, when the delay in gastric emptying was largely
attenuated. This ﬁnding is consistent with previous stud-
ies showing that the reduction in postprandial glycemia
and insulin secretion is largely diminished, when the ef-
fects of the incretin on the stomach are antagonized (10).
Taken together, these studies underline the importance of
delayed gastric emptying as the primary factor driving the
reduction in postprandial glycemia during acute GLP-1
administration.
What are the mechanisms conferring the induction of
tolerance against the GLP-1 effects on gastric emptying?
One possibility would be a downregulation or desensitiza-
tion of the GLP-1 receptor in response to chronically ele-
vated GLP-1 levels. Indeed, receptor desensitization has
been described for GIP (22), which shares many intra-
cellular signaling steps with GLP-1. For GLP-1, chronic ex-
posure to a receptor antagonist in mice in vivo did not result
in a signiﬁcant receptor downregulation or attenuation of its
glucoregulatory effects (23), thereby rendering this expla-
nation less likely.
The alternative hypothesis would be tachyphylaxis to
the effects of GLP-1 at the level of the vagal nerve. Such a
mechanism would explain why the effects of GLP-1 on gas-
tric emptying are obviously more affected by the induction of
tolerance than the islet hormone responses (24). Further-
more, chronic adaptation of the autonomous nervous sys-
tem is a well-recognized principle, which is also responsible
for many other phenomena, such as hypoglycemia un-
awareness (25), tolerance to b-adrenergic agonists (26),
and opioid tolerance (27). Finally, the time kinetics of
tolerance induction observed in the current study (within
;5 h) are more typical for the mechanism of tachy-
phylaxis than for receptor downregulation, which usually
requires longer periods of exposure. The hypothesis of
vagal nervous tachyphylaxis is further supported by the
plasma concentrations of PP, which are thought to mirror
the systemic level of vagal nervous activation (10,28). In
fact, PP levels were markedly suppressed by GLP-1 during
the ﬁrst meal course, but slightly elevated during the second
test meal, suggesting a more pronounced inhibition of
parasympathetic outﬂow during the ﬁr s tt e s tm e a l .T h u s ,
GLP-1 seems to inhibit gastric emptying primarily through
inhibition of the vagal nerve (28), but this mechanism is
subject to rapid tachyphylaxis after chronic GLP-1 exposure.
The present data give rise to consider which of the
multiple GLP-1 effects are subject to rapid tachyphylaxis
and which are not. Clearly, the GLP-1–induced inhibition
of gastric emptying was less pronounced during the sec-
ond meal course compared with the ﬁrst meal. In contrast,
the quantitative amount of insulin released after the sec-
ond test meal was even greater than after the ﬁrst test
meal, thereby arguing against an attenuation of the insu-
linotropic effect of GLP-1 during continuous exposure. For
glucagon, an opposite picture was found, with a marked
suppression after the ﬁrst meal and higher levels after
the second meal. However, because these postprandial
changes in insulin and glucagon levels were primarily
driven by the changes in gastric emptying, it is impossible
to draw ﬁrm conclusions regarding a rapid tachyphylaxis
to the GLP-1 effects on islet hormone secretion from this
study. By taking into account the results obtained from the
various long-term studies with GLP-1 analogs (24,29,30),
there is little reason to assume the presence of such
a mechanism. Thus, although the GLP-1 actions on the
stomach seem to critically depend on the time kinetics of
GLP-1 levels, its insulinotropic and glucagon static effects
are likely less dependent on the ﬂuctuations in GLP-1 levels.
Of note, glucagon concentrations increased after the
ingestion of the test meal. This is in contrast with previous
studies showing a signiﬁcant decline in glucagon levels
after intravenous or oral glucose ingestion (31,32). This
apparent discrepancy is most likely due to the high amino
acid content of the test meal, which is known to stimulate
rather than suppress glucagon secretion (33).
Another interesting ﬁnding from this study is the alter-
ation in GIP secretion by GLP-1. During the ﬁrst test meal,
the GLP-1–induced retardation of gastric emptying led to
a signiﬁcant delay in GIP secretion. Given the importance
of GIP as a physiologic incretin hormone (15,34), this
might theoretically impair postprandial insulin responses
and thus worsen glucose control. In the present experi-
ments, the concentration time patterns of insulin and
C-peptide seemed to closely mirror the respective GIP
levels, thereby emphasizing the role of GIP as a physiologic
enhancer of postprandial insulin release. In addition, GIP has
also been shown to augment glucagon secretion in healthy
humans (35). It is therefore possible that the differences in
the postprandial concentrations of glucagon between the
two test meals were also partly secondary to the changes
in GIP release. However, given the complexity of these
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nal motility, gut hormone release, and islet hormone se-
cretion, it is difﬁcult to fully elucidate these relationships on
the basis of the present experiments.
Although the present studies in healthy individuals do
not allow for ﬁrm conclusions regarding the therapeutic
use of GLP-1–based drugs, it would be tempting to spec-
ulate that the development of tachyphylaxis might be in-
volved in the unequal susceptibility of patients to develop
nausea when treated with either short- or long-acting GLP-1
analogs. It would therefore be of interest to examine the
induction of tachyphylaxis in patients with type 2 diabetes
during the chronic treatment with different GLP-1 analogs.
In conclusion, the delay in gastric emptying by GLP-1 is
markedly attenuated during continued exposure to high
GLP-1 concentrations. Most likely, this is due to the in-
duction of tachyphylaxis at the level of vagal nervous ac-
tivation. As a consequence, postprandial glucose control
by GLP-1 is attenuated after its chronic administration.
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